The customary approach to early-phase clinical trial design, where the focus is on identification of the maximum tolerated dose, is not always suitable for noncytotoxic or other targeted therapies.
ATLANTA and SAN FRANCISCO, Nov. 18, 2025 /PRNewswire/ -- Equifax® (NYSE: EFX) and Kikoff, a personal finance platform that expands access to credit and financial services, today announced that Optimal ...
Powered by the Equifax Cloud™ and Patented EFX.AI Capabilities, Optimal Path Gives Organizations a Powerful Tool to Help U.S. Consumers Advance Financial Health and Achieve Personalized Credit Score ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results